<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31405128</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>16</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3903</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20163903</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is a common form of dementia among early-onset cases. Several genetic factors for FTD have been revealed, but a large proportion of FTD cases still have an unidentified genetic origin. Recent studies highlighted common pathobiological mechanisms among neurodegenerative diseases. In the present study, we investigated a panel of candidate genes, previously described to be associated with FTD and/or other neurodegenerative diseases by targeted next generation sequencing (NGS). We focused our study on sporadic FTD (sFTD), devoid of disease-causing mutations in <i>GRN</i>, <i>MAPT</i> and <i>C9orf72</i>. Since genetic factors have a substantially higher pathogenetic contribution in early onset patients than in late onset dementia, we selected patients with early onset (&lt;65 years). Our study revealed that, in 50% of patients, rare missense potentially pathogenetic variants in genes previously associated with Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis and Lewy body dementia (<i>GBA</i>, <i>ABCA7</i>, <i>PARK7</i>, <i>FUS</i>, <i>SORL1</i>, <i>LRRK2</i>, <i>ALS2</i>), confirming genetic pleiotropy in neurodegeneration. In parallel, a synergic genetic effect on FTD is suggested by the presence of variants in five different genes in one single patient. Further studies employing genome-wide approaches might highlight pathogenic variants in novel genes that explain the still missing heritability of FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciani</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonvicini</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scassellati</LastName><ForeName>Catia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrara</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maj</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Genomic Statistics and Bioinformatics, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fostinelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2836-8141</Identifier><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy. lbenussi@fatebenefratelli.eu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PATHWAYS-200-059</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>Ricerca Corrente</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">early onset</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">genetic rare variants</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">next generation sequencing</Keyword><Keyword MajorTopicYN="N">sporadic cases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31405128</ArticleId><ArticleId IdType="pmc">PMC6721049</ArticleId><ArticleId IdType="doi">10.3390/ijms20163903</ArticleId><ArticleId IdType="pii">ijms20163903</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ratnavalli E., Brayne C., Dawson K., Hodges J.R. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615&#x2013;1621. doi: 10.1212/WNL.58.11.1615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.11.1615</ArticleId><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M., Ishikawa T., Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement. Geriatr. Cogn. Disord. 2004;17:265&#x2013;268. doi: 10.1159/000077151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000077151</ArticleId><ArticleId IdType="pubmed">15178933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014. doi: 10.1212/WNL.0b013e31821103e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J. Neurol. Neurosurg. Psychiatry. 2011;82:476&#x2013;486. doi: 10.1136/jnnp.2010.212225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.212225</ArticleId><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R.C., Goetz C.G., Golbe L.I., Grafman J., Growdon J.H., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology. 1996;47:1&#x2013;9. doi: 10.1212/WNL.47.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.1.1</ArticleId><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496&#x2013;503. doi: 10.1212/WNL.0b013e31827f0fd1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Rovelet-Lecrux A. Recent insights into the molecular genetics of dementia. Trends Neurosci. 2009;32:451&#x2013;461. doi: 10.1016/j.tins.2009.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2009.05.005</ArticleId><ArticleId IdType="pmc">PMC2864783</ArticleId><ArticleId IdType="pubmed">19640594</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E.M., Falcone D., Suh E., Irwin D.J., Chen-Plotkin A.S., Lee E.B., Xie S.X., Van Deerlin V.M., Grossman M. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 2013;70:1411&#x2013;1417. doi: 10.1001/jamaneurol.2013.3956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.3956</ArticleId><ArticleId IdType="pmc">PMC3906581</ArticleId><ArticleId IdType="pubmed">24081456</ArticleId></ArticleIdList></Reference><Reference><Citation>Fostinelli S., Ciani M., Zanardini R., Zanetti O., Binetti G., Ghidoni R., Benussi L. The heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. J. Alzheimers Dis. 2018;61:753&#x2013;760. doi: 10.3233/JAD-170661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170661</ArticleId><ArticleId IdType="pubmed">29226869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill C.M., Bertram L. Towards unveiling the genetics of neurodegenerative diseases. Semin. Neurol. 2011;31:531&#x2013;541. doi: 10.1055/s-0031-1299791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0031-1299791</ArticleId><ArticleId IdType="pubmed">22266890</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement. 2013;9:63&#x2013;75. doi: 10.1016/j.jalz.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N., Nuytemans K., van der Zee J., Gijselinck I., Engelborghs S., Theuns J., Kumar-Singh S., Pickut B.A., Pals P., Dermaut B., et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch. Neurol. 2007;64:1436&#x2013;1446. doi: 10.1001/archneur.64.10.1436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1436</ArticleId><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandrovcova J., Anaya F., Kay V., Lees A., Hardy J., de Silva R. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr. Alzheimer Res. 2010;8:726&#x2013;734. doi: 10.2174/156720510793611619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510793611619</ArticleId><ArticleId IdType="pubmed">20704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S., Sato Y., Takashima A. Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. Neurobiol. Aging. 2018;69:26&#x2013;32. doi: 10.1016/j.neurobiolaging.2018.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.014</ArticleId><ArticleId IdType="pubmed">29852407</ArticleId></ArticleIdList></Reference><Reference><Citation>Origone P., Geroldi A., Lamp M., Sanguineri F., Caponnetto C., Cabona C., Gotta F., Trevisan L., Bellone E., Manganelli F., et al. Role of MAPT in Pure Motor Neuron Disease: Report of a Recurrent Mutation in Italian Patients. Neurodegener. Dis. 2018;18:310&#x2013;314. doi: 10.1159/000497820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000497820</ArticleId><ArticleId IdType="pubmed">30893702</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I., van der Zee J., Hannequin D., Gijselinck I., Campion D., Puel M., Laquerri&#xe8;re A., De Pooter T., Camuzat A., Van den Broeck M., et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum. Mutat. 2007;9:846&#x2013;855. doi: 10.1002/humu.20520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20520</ArticleId><ArticleId IdType="pubmed">17436289</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L., Binetti G., Sina E., Gigola L., Bettecken T., Meitinger T., Ghidoni R. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol. Aging. 2008;29:427&#x2013;435. doi: 10.1016/j.neurobiolaging.2006.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.10.028</ArticleId><ArticleId IdType="pubmed">17157414</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L., Ghidoni R., Pegoiani E., Moretti D.V., Zanetti O., Binetti G. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol. Dis. 2009;33:379&#x2013;385. doi: 10.1016/j.nbd.2008.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.11.008</ArticleId><ArticleId IdType="pubmed">19101631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Broeckhoven C., Cruts M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: An update. Hum. Mutat. 2008;12:1373&#x2013;1386. doi: 10.1002/humu.20785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20785</ArticleId><ArticleId IdType="pubmed">18543312</ArticleId></ArticleIdList></Reference><Reference><Citation>Marogianni C., Rikos D., Provatas A., Dadouli K., Ntellas P., Tsitsi P., Patrinos G., Dardiotis E., Hadjigeorgiou G., Xiromerisiou G. The role of C9orf72 in neurodegenerative disorders: A systematic review, an updated meta-analysis, and the creation of an online database. Neurobiol. Aging. 2019;24 doi: 10.1016/j.neurobiolaging.2019.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.04.012</ArticleId><ArticleId IdType="pubmed">31126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Olszewska D.A., Lonergan R., Fallon E.M., Lynch T. Genetics of Frontotemporal Dementia. Curr. Neurol. Neurosci. Rep. 2016;16:107. doi: 10.1007/s11910-016-0707-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-016-0707-9</ArticleId><ArticleId IdType="pubmed">27878525</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Al-Chalabi A., Chio A., Hardiman O., Kiernan M.C., Rohrer J.D., Rowe J., Seeley W., Talbot K. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry. 2017;88:1042&#x2013;1044. doi: 10.1136/jnnp-2017-315995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciani M., Benussi L., Bonvicini C., Ghidoni R. Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. Front. Neurosci. 2019;13:506. doi: 10.3389/fnins.2019.00506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00506</ArticleId><ArticleId IdType="pmc">PMC6532367</ArticleId><ArticleId IdType="pubmed">31156380</ArticleId></ArticleIdList></Reference><Reference><Citation>Capozzo R., Sassi C., Hammer M.B., Arcuti S., Zecca C., Barulli M.R., Tortelli R., Gibbs J.R., Crews C., Seripa D. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimers Dement. 2017;13:858&#x2013;869. doi: 10.1016/j.jalz.2017.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.011</ArticleId><ArticleId IdType="pmc">PMC6232845</ArticleId><ArticleId IdType="pubmed">28264768</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607. doi: 10.1016/j.neuron.2004.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.11.005</ArticleId><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T., van der Zee J., Sleegers K., Engelborghs S., Vandenberghe R., Gijselinck I., Van den Broeck M., Mattheijssens M., Peeters K., De Deyn P.P. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74:366&#x2013;371. doi: 10.1212/WNL.0b013e3181ccc732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ccc732</ArticleId><ArticleId IdType="pubmed">20124201</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeeck C., Deng Q., Dejesus-Hernandez M., Taylor G., Ceballos-Diaz C., Kocerha J., Golde T., Das P., Rademakers R., Dickson D.W., et al. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol. Neurodegener. 2012;7:53. doi: 10.1186/1750-1326-7-53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-53</ArticleId><ArticleId IdType="pmc">PMC3519790</ArticleId><ArticleId IdType="pubmed">23046583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H., Kara E., Bandopadhyay R., Hardy J., Holton J., Xiromerisiou G., Lees A., Houlden H., Revesz T. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. Neurobiol. Aging. 2013;34:2889. doi: 10.1016/j.neurobiolaging.2013.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.04.011</ArticleId><ArticleId IdType="pmc">PMC3906605</ArticleId><ArticleId IdType="pubmed">23664753</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622. doi: 10.1016/S1474-4422(13)70090-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Murray M.E., Whitwell J.L., Tosakulwong N., Weigand S.D., Petrucelli L., Liesinger A.M., Petersen R.C., Parisi J.E., Dickson D.W. Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol. 2016;131:571&#x2013;585. doi: 10.1007/s00401-016-1537-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Wang Y., Vandrovcova J., Guelfi S., Witeolar A., Karch C.M., Schork A.J., Fan C.C., Brewer J.B. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J. Neurol. Neurosurg. Psychiatry. 2017;88:152&#x2013;164. doi: 10.1136/jnnp-2016-314411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314411</ArticleId><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Breza M., Koutsis G., Karadima G., Potagas C., Kartanou C., Papageorgiou S.G., Paraskevas G.P., Kapaki E., Stefanis L., Panas M. The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia. Neurosci. Lett. 2018;672:136&#x2013;139. doi: 10.1016/j.neulet.2017.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.12.015</ArticleId><ArticleId IdType="pubmed">29233723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez L., Dube U., Davis A.A., Fernandez M.V., Budde J., Cooper B., Diez-Fairen M., Ortega-Cubero S., Pastor P., Perlmutter J.S., et al. Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front. Neurosci. 2018;10:230. doi: 10.3389/fnins.2018.00230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00230</ArticleId><ArticleId IdType="pmc">PMC5902712</ArticleId><ArticleId IdType="pubmed">29692703</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira A.H., Chiasserini D., Beccari T., Parnetti L. Glucocerebrosidase in Parkinson&#x2019;s disease: Insights into pathogenesis and prospects for treatment. Mov. Disord. 2016;6:830&#x2013;835. doi: 10.1002/mds.26616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26616</ArticleId><ArticleId IdType="pubmed">27091307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P.K., Lopez G., Schiffmann R., Barton N.W., Weinreb N.J., Sidransky E. Gaucher disease: Progress and ongoing challenges. Mol. Genet. Metab. 2017;120:8&#x2013;21. doi: 10.1016/j.ymgme.2016.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2016.11.006</ArticleId><ArticleId IdType="pmc">PMC5425955</ArticleId><ArticleId IdType="pubmed">27916601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Ross O.A., Kun-Rodrigues C., Hernandez D.G., Orme T., Eicher J.D., Shepherd C.E., Parkkinen L., Darwent L., Heckman M.G., et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17:64&#x2013;74. doi: 10.1016/S1474-4422(17)30400-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30400-3</ArticleId><ArticleId IdType="pmc">PMC5805394</ArticleId><ArticleId IdType="pubmed">29263008</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Deng L., Zhong Y., Yi M. The Association between E326K of GBA and the Risk of Parkinson&#x2019;s Disease. Parkinson Dis. 2018:1048084. doi: 10.1155/2018/1048084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1048084</ArticleId><ArticleId IdType="pmc">PMC5901859</ArticleId><ArticleId IdType="pubmed">29808112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin S., Hughes D., Mehta A., Schapira A.H.V. Neurological effects of glucocerebrosidase gene mutations. Eur. J. Neurol. 2019;26:388-e29. doi: 10.1111/ene.13837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13837</ArticleId><ArticleId IdType="pmc">PMC6492454</ArticleId><ArticleId IdType="pubmed">30315684</ArticleId></ArticleIdList></Reference><Reference><Citation>Berge-Seidl V., Pihlstr&#xf8;m L., Maple-Gr&#xf8;dem J., Forsgren L., Linder J., Larsen J.P., Tysnes O.B., Toft M. The GBA variant E326K is associated with Parkinson&#x2019;s disease and explains a genome-wide association signal. Neurosci. Lett. 2017;658:48&#x2013;52. doi: 10.1016/j.neulet.2017.08.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.08.040</ArticleId><ArticleId IdType="pubmed">28830825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata I.F., Johnson C.O., Leverenz J.B., Weintraub D., Trojanowski J.Q., Van Deerlin V.M., Ritz B., Rausch R., Factor S.A., Wood-Siverio C., et al. Large-scale exploratory genetic analysis of cognitive impairment in Parkinson&#x2019;s disease. Neurobiol. Aging. 2017;56:211.e1&#x2013;211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.04.009</ArticleId><ArticleId IdType="pmc">PMC5536182</ArticleId><ArticleId IdType="pubmed">28526295</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.L., Mizielinska S., Edgar J.R., Nielsen T.T., Marshall S., Norona F.E., Robbins M., Damirji H., Holm I.E., Johannsen P., et al. Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 2015;130:511&#x2013;523. doi: 10.1007/s00401-015-1475-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1475-3</ArticleId><ArticleId IdType="pmc">PMC4575387</ArticleId><ArticleId IdType="pubmed">26358247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H., Zhang J., Makinson S.R., Cahill M.K., Kelley K.W., Huang H.Y., Shang Y., Oldham M.C., Martens L.H., Gao F., et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell. 2016;165:921&#x2013;935. doi: 10.1016/j.cell.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.001</ArticleId><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L., Ciani M., Tonoli E., Morbin M., Palamara L., Albani D., Fusco F., Forloni G., Glionna M., Baco M., et al. Loss of exosomes in progranulin-associated frontotemporal dementia. Neurobiol. Aging. 2016;40:41&#x2013;49. doi: 10.1016/j.neurobiolaging.2016.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.01.001</ArticleId><ArticleId IdType="pubmed">26973102</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A., Horvitz H.R. A C9orf72 ALS/FTD Ortholog Acts in Endolysosomal Degradation and Lysosomal Homeostasis. Curr. Biol. 2018;28:1522&#x2013;1535. doi: 10.1016/j.cub.2018.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2018.03.063</ArticleId><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K.R., Damiano J., Franceschetti S., Carpenter S., Canafoglia L., Morbin M., Rossi G., Pareyson D., Mole S.E., Staropoli J.F., et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 2012;90:1102&#x2013;1107. doi: 10.1016/j.ajhg.2012.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.04.021</ArticleId><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida M.R., Mac&#xe1;rio M.C., Ramos L., Baldeiras I., Ribeiro M.H., Santana I. Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol. Aging. 2016;41:200.e1&#x2013;200.e5. doi: 10.1016/j.neurobiolaging.2016.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.019</ArticleId><ArticleId IdType="pubmed">27021778</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers B.M., Rodriguez-Navas C., Tesla R.J., Prange-Kiel J., Wasser C.R., Yoo K.S., McDonald J., Cenik B., Ravenscroft T.A., Plattner F., et al. Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency. Cell. Rep. 2017;20:2565&#x2013;2574. doi: 10.1016/j.celrep.2017.08.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.056</ArticleId><ArticleId IdType="pmc">PMC5757843</ArticleId><ArticleId IdType="pubmed">28903038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.S., Fitzgerald M.L., Kang K., Okuhira K., Bell S.A., Manning J.J., Koehn S.L., Lu N., Moore K.J., Freeman M.W. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 2005;280:3989&#x2013;3995. doi: 10.1074/jbc.M412602200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412602200</ArticleId><ArticleId IdType="pubmed">15550377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.S., Weickert C.S., Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 2008;104:1145&#x2013;1166. doi: 10.1111/j.1471-4159.2007.05099.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05099.x</ArticleId><ArticleId IdType="pubmed">17973979</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K., Abe-Dohmae S., Yokoyama S., St George-Hyslop P., Fraser P.E. ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J. Biol. Chem. 2015;290:24152&#x2013;24165. doi: 10.1074/jbc.M115.655076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.655076</ArticleId><ArticleId IdType="pmc">PMC4591804</ArticleId><ArticleId IdType="pubmed">26260791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E., De Roeck A., Van den Bossche T., Van Cauwenberghe C., Bettens K., Vermeulen S., Mattheijssens M., Peeters K., Engelborghs S., Vandenbulcke M., et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer&#x2019;s disease patients: a targeted resequencing study. Lancet Neurol. 2015;14:814&#x2013;822. doi: 10.1016/S1474-4422(15)00133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00133-7</ArticleId><ArticleId IdType="pubmed">26141617</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roeck A., Van den Bossche T., van der Zee J., Verheijen J., De Coster W., Van Dongen J., Dillen L., Baradaran-Heravi Y., Heeman B., Sanchez-Valle R., et al. Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer&#x2019;s disease. Acta Neuropathol. 2017;134:475&#x2013;487. doi: 10.1007/s00401-017-1714-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1714-x</ArticleId><ArticleId IdType="pmc">PMC5563332</ArticleId><ArticleId IdType="pubmed">28447221</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S., Stefansson H., Jonsson T., Johannsdottir H., Ingason A., Helgason H., Sulem P., Magnusson O.T., Gudjonsson S.A., Unnsteinsdottir U., et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat. Genet. 2015;47:445&#x2013;447. doi: 10.1038/ng.3246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3246</ArticleId><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., Charbonnier C., Grenier-Boley B., Quenez O., Le Guennec K., Nicolas G., Chauhan G., Wallon D., Rousseau S., Richard A.C., et al. Contribution to Alzheimer&#x2019;s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol. Aging. 2017;59:220.e1&#x2013;220.e9. doi: 10.1016/j.neurobiolaging.2017.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.07.001</ArticleId><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuele E., Peros E., Tomaino C., Feudatari E., Bernardi L., Binetti G., Maletta R., Micieli G., Bruni A.C., Geroldi D. Association between small apolipoprotein(a) isoforms and frontotemporal dementia in humans. Neurosci. Lett. 2003;353:201&#x2013;204. doi: 10.1016/j.neulet.2003.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.09.046</ArticleId><ArticleId IdType="pubmed">14665416</ArticleId></ArticleIdList></Reference><Reference><Citation>Antipova D., Bandopadhyay R. Expression of DJ-1 in Neurodegenerative Disorders. Adv. Exp. Med. Biol. 2017;1037:25&#x2013;43. doi: 10.1007/978-981-10-6583-5_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-10-6583-5_3</ArticleId><ArticleId IdType="pubmed">29147901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijioka M., Inden M., Yanagisawa D., Kitamura Y. DJ-1/PARK7: A New Therapeutic Target for Neurodegenerative Disorders. Biol. Pharm. Bull. 2017;40:548&#x2013;552. doi: 10.1248/bpb.b16-01006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b16-01006</ArticleId><ArticleId IdType="pubmed">28458339</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Liu X., Shen J., Tian W., Fang R., Li B., Ma J., Cao L., Chen S., Li G., et al. The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia. Aging Dis. 2018;9:696&#x2013;705. doi: 10.14336/AD.2018.0208.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2018.0208</ArticleId><ArticleId IdType="pmc">PMC6065298</ArticleId><ArticleId IdType="pubmed">30090657</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E., Colombrita C., Gumina V., Borghi M.O., Dusi S., Doretti A., Fagiolari G., Invernizzi F., Moggio M., Tiranti V., et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol. Commun. 2016;4:47. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigu&#xe8;re N., Pacelli C., Saumure C., Bourque M.J., Matheoud D., Levesque D., Slack R.S., Park D.S., Trudeau L.&#xc9;. Comparative analysis of Parkinson&#x2019;s disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons. J. Biol. Chem. 2018;293:9580&#x2013;9593. doi: 10.1074/jbc.RA117.000499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA117.000499</ArticleId><ArticleId IdType="pmc">PMC6016451</ArticleId><ArticleId IdType="pubmed">29700116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., Mackenzie I.R. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;2931. doi: 10.1093/brain/awp214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp214</ArticleId><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradfield N.I., McLean C., Drago J., Darby D.G., Ames D. Rapidly progressive Fronto-temporal dementia (FTD) associated with Frontotemporal lobar degeneration (FTLD) in the presence of Fused in Sarcoma (FUS) protein: a rare, sporadic, and aggressive form of FTD. Int. Psychogeriatr. 2017;29:1743&#x2013;1746. doi: 10.1017/S1041610217001193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610217001193</ArticleId><ArticleId IdType="pubmed">28660843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19:R46&#x2013;R64. doi: 10.1093/hmg/ddq137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo K.Y., Sultana J., King A.E., Atkinson R.A.K., Warraich S.T., Sundaramoorthy V., Blair I., Farg M.A., Atkin J.D. ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1. Cell. Death Discov. 2015;1:15030. doi: 10.1038/cddiscovery.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddiscovery.2015.30</ArticleId><ArticleId IdType="pmc">PMC4979432</ArticleId><ArticleId IdType="pubmed">27551461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T., Hokonohara T., Yamasaki R., Miura S., Kituchi H., Iwaki A., Tashiro H., Furuya H., Nagara Y., Ohyagi Y., et al. Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol. 2010;119:355&#x2013;364. doi: 10.1007/s00401-009-0621-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0621-1</ArticleId><ArticleId IdType="pubmed">19967541</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Cleveland D.W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 2011;21:904&#x2013;919. doi: 10.1016/j.conb.2011.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2011.05.029</ArticleId><ArticleId IdType="pmc">PMC3228892</ArticleId><ArticleId IdType="pubmed">21813273</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel F.C., Kahle P.J. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. FEBS J. 2011;278:3550&#x2013;3568. doi: 10.1111/j.1742-4658.2011.08258.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2011.08258.x</ArticleId><ArticleId IdType="pubmed">21777389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., De Stafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458. doi: 10.1038/ng.2802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G., Charbonnier C., Wallon D., Quenez O., Bellenguez C., Grenier-Boley B., Rousseau S., Richard A.C., Rovelet-Lecrux A., Le Guennec K., et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer&#x2019;s disease. Mol. Psychiatry. 2016;21:831&#x2013;836. doi: 10.1038/mp.2015.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.121</ArticleId><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O.M., Rudolph I.M., Willnow T.E. Risk factor SORL1: from genetic association to functional validation in Alzheimer&#x2019;s disease. Acta Neuropathol. 2016;132:653&#x2013;665. doi: 10.1007/s00401-016-1615-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1615-4</ArticleId><ArticleId IdType="pmc">PMC5073117</ArticleId><ArticleId IdType="pubmed">27638701</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuccaro M.L., Carney R.M., Zhang Y., Bohm C., Kunkle B.W., Vardarajan B.N., Whitehead P.L., Cukier H.N., Mayeux R., St George-Hyslop P., et al. SORL1 mutations in early- and late-onset Alzheimer disease. Neurol Genet. 2016;2:e116. doi: 10.1212/NXG.0000000000000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000116</ArticleId><ArticleId IdType="pmc">PMC5082932</ArticleId><ArticleId IdType="pubmed">27822510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.M., Highton-Williamson E., Caga J., Thornton N., Ramsey E., Zoing M., Kim W.S., Halliday G.M., Piguet O., Hodges J.R., et al. Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. J. Alzheimers Dis. 2018;61:773&#x2013;783. doi: 10.3233/JAD-170660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170660</ArticleId><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Telpoukhovskaia M.A., Bahr B.A., Chen X., Gan L. Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Curr. Opin. Neurobiol. 2018;48:52&#x2013;58. doi: 10.1016/j.conb.2017.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2017.09.005</ArticleId><ArticleId IdType="pubmed">29028540</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H., van der Lee S.J., Hulsman M., Wong T.H., van Rooij J.G., Weiss M., Louwersheimer E., Wolters F.J., Amin N., Uitterlinden A.G., et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer&#x2019;s disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 2017;25:973&#x2013;981. doi: 10.1038/ejhg.2017.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2017.87</ArticleId><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="pubmed">28537274</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva C.P., de M Abreu G., Cabello Acero P.H., Campos M.J., Pereira J.S., de A Ramos S.R., Nascimento C.M., Voigt D.D., Rosso A.L., Leite M.A., et al. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson&#x2019;s disease. J. Neurol. Sci. 2017;381:160&#x2013;164. doi: 10.1016/j.jns.2017.08.3249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.08.3249</ArticleId><ArticleId IdType="pubmed">28991672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K., Otomo A., Ueda M.T., Hiratsuka Y., Suzuki-Utsunomiya K., Sugiyama J., Murakoshi S., Mitsui S., Ono S., Nakagawa S., et al. Altered oligomeric states in pathogenic ALS2 variants associated with juvenile motor neuron diseases cause loss of ALS2-mediated endosomal function. J. Biol. Chem. 2018;293:17135&#x2013;17153. doi: 10.1074/jbc.RA118.003849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003849</ArticleId><ArticleId IdType="pmc">PMC6222102</ArticleId><ArticleId IdType="pubmed">30224357</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu L., Zhang Y., Pan H., Xu Q., Guo J., Tang B., Sun Q. Clinical Heterogeneity Among LRRK2 Variants in Parkinson&#x2019;s Disease: A Meta-Analysis. Front. Aging Neurosci. 2018;10:283. doi: 10.3389/fnagi.2018.00283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00283</ArticleId><ArticleId IdType="pmc">PMC6156433</ArticleId><ArticleId IdType="pubmed">30283330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho D.H., Kim H., Nam D., Sim H., Kim J., Kim H.G., Son I., Seol W. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase. Cell. Biochem. Funct. 2018;36:431&#x2013;442. doi: 10.1002/cbf.3364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3364</ArticleId><ArticleId IdType="pubmed">30411383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y.J., Ugolino J., Brady N.R., Hamacher-Brady A., Wang J. Systemic deregulation of autophagy upon loss of ALS- and FTD-linked C9orf72. Autophagy. 2017;13:1254&#x2013;1255. doi: 10.1080/15548627.2017.1299312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1299312</ArticleId><ArticleId IdType="pmc">PMC5529072</ArticleId><ArticleId IdType="pubmed">28319438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan P., Yue Z. Deregulation of autophagy and vesicle trafficking in Parkinson&#x2019;s disease. Neurosci. Lett. 2018 doi: 10.1016/j.neulet.2018.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.013</ArticleId><ArticleId IdType="pmc">PMC6173655</ArticleId><ArticleId IdType="pubmed">29627340</ArticleId></ArticleIdList></Reference><Reference><Citation>Caesar M., Felk S., Aasly J.O., Gillardon F. Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2 (R1441G) mutant mice and in primary human fibroblasts of LRRK2 (G2019S) mutation carriers. Neuroscience. 2015;284:311&#x2013;324. doi: 10.1016/j.neuroscience.2014.09.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.09.070</ArticleId><ArticleId IdType="pubmed">25301747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Jara J.H., Sekerkova G., Yasvoina M.V., Martina M., &#xd6;zdinler P.H. Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms. Hum. Mol. Genet. 2016;25:1074&#x2013;1087. doi: 10.1093/hmg/ddv631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv631</ArticleId><ArticleId IdType="pmc">PMC4764190</ArticleId><ArticleId IdType="pubmed">26755825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wren M.C., Zhao J., Liu C.C., Murray M.E., Atagi Y., Davis M.D., Fu Y., Okano H.J., Ogaki K., Strongosky A.J., et al. Frontotemporal dementia-associated N279K Tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Mol. Neurodegener. 2015;10:46. doi: 10.1186/s13024-015-0042-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0042-7</ArticleId><ArticleId IdType="pmc">PMC4572645</ArticleId><ArticleId IdType="pubmed">26373282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonvicini C., Scassellati C., Benussi L., Di Maria E., Maj C., Ciani M., Fostinelli S., Mega A., Bocchetta M., Lanzi G., et al. Next Generation Sequencing Analysis in Early Onset Dementia Patients. J. Alzheimers Dis. 2019;67:243&#x2013;256. doi: 10.3233/JAD-180482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180482</ArticleId><ArticleId IdType="pmc">PMC6398561</ArticleId><ArticleId IdType="pubmed">30530974</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-P&#xe9;rez J.M., Candela H., Micol J.L. Understanding synergy in genetic interactions. Trends Genet. 2009;25:368&#x2013;376. doi: 10.1016/j.tig.2009.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2009.06.004</ArticleId><ArticleId IdType="pubmed">19665253</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Giau V.V., Senanarong V., Bagyinszky E., An S.S.A., Kim S. Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimer&#x2019;s Disease. Int. J. Mol. Sci. 2019;20:1514. doi: 10.3390/ijms20061514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061514</ArticleId><ArticleId IdType="pmc">PMC6471359</ArticleId><ArticleId IdType="pubmed">30917570</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303. doi: 10.1101/gr.107524.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Witvliet D.K., Strokach A., Giraldo-Forero A.F., Teyra J., Colak R., Kim P.M. ELASPIC web-server: proteome-wide structure-based prediction of mutation effects on protein stability and binding affinity. Bioinformatics. 2016;32 doi: 10.1093/bioinformatics/btw031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw031</ArticleId><ArticleId IdType="pubmed">26801957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>